A new study published in the journal Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association links semaglutide, the active ingredient in Ozempic and Wegovy, to a lower risk of Alzheimer’s disease.
Researchers at Case Western Reserve School of Medicine analyzed three years of electronic records from nearly one million Americans with type 2 diabetes. They compared patients using semaglutide with those prescribed seven other antidiabetic drugs, including metformin, dipeptidyl-peptidase-4 inhibitors, and other GLP-1 receptor agonists.
Patients prescribed semaglutide had a 40% to 70% reduced risk of first-time Alzheimer’s diagnosis compared with patients taking the other diabetes medications.
Rong Xu, a biomedical informatics professor at Case Western Reserve University and the lead researcher, said, 'The result is what we expected.' Xu said prior studies suggest semaglutide may help reduce inflammation in the body, prevent neuron damage, promote weight loss, control diabetes and prevent cardiovascular disease, and may also help curb the urge to smoke and drink.
Xu said the study was not designed to test whether semaglutide lowers Alzheimer’s risk in people without diabetes. 'Diabetes itself is a risk factor [for Alzheimer’s],' Xu said, adding that the team wanted to see whether people with diabetes would have better outcomes with semaglutide than with other diabetes medications.
Researchers said they cannot say semaglutide lowers Alzheimer’s risk, only that there is a link. They said more research is needed.
The numbers come first. If a drug already used for diabetes and weight loss can also cut the risk of a devastating brain disease, that is not just a medical headline — it is a signal about incentives, research and the value of private innovation.
Capital rewards clear rules, and the market has already voted on semaglutide with demand. What comes next will be decided by evidence, not hype, but the finding adds another reason to watch how the free enterprise system turns one breakthrough into many.
